Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 19, 2023 01:00 ET | Source: Sequana Medical NV

Sequana Medical announces additional alfapump data supporting strong and durable clinical profile; PMA on track for year-end submission

PRESS RELEASEREGULATED INFORMATION – INSIDE INFORMATION19 October 2023, 07:00 am CEST One-year alfapump data from POSEIDON shows safety and strong efficacy profile is maintained at 12...
October 18, 2023 01:00 ET | Source: Sequana Medical NV

Sequana Medical announces initial positive data from MOJAVE, a US Phase 1/2a study of DSR® 2.0 for treatment of heart failure through breaking vicious cycle of cardiorenal syndrome

PRESS RELEASEREGULATED INFORMATION – INSIDE INFORMATION18 October 2023, 07:00 am CEST First two US patients from non-randomized cohort successfully treated with DSR 2.0Initial data indicate that...
October 06, 2023 01:00 ET | Source: Sequana Medical NV

Sequana Medical announces Extraordinary General Meeting of Shareholders on 10 November 2023

PRESS RELEASEREGULATED INFORMATION06 October 2023, 07:00 am CEST Ghent, Belgium – 06 October 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer...
October 04, 2023 12:00 ET | Source: Sequana Medical NV

SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES

PRESS RELEASEREGULATED INFORMATION4 October 2023, 06:00 pm CEST Ghent, Belgium, 4 October 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the...
September 14, 2023 01:00 ET | Source: Sequana Medical NV

Sequana Medical announces H1 2023 results and provides business update

PRESS RELEASEREGULATED INFORMATION – INSIDE INFORMATION14 September 2023, 07:00 CEST alfapump® – strong pivotal POSEIDON data presented at leading international liver congress / on track to file...
September 06, 2023 01:00 ET | Source: Sequana Medical NV

Sequana Medical Notice of 2023 Half-year Results and Business Update

Ghent, Belgium – 6 September 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of fluid overload in liver disease, heart failure...
July 10, 2023 01:00 ET | Source: Sequana Medical NV

Sequana Medical announces first patient enrolled in MOJAVE, a US randomized controlled Phase 1/2a study of DSR® 2.0 for treatment of congestive heart failure

PRESS RELEASE US study seeking to confirm strong efficacy data reported in RED DESERT and SAHARA Initial data expected in Q4 2023 Ghent, Belgium – 10 July 2023 – Sequana Medical NV (Euronext...
July 06, 2023 01:00 ET | Source: Sequana Medical NV

1,000th alfapump® implant completed

Extensive real world alfapump experience derisks planned US & Canadian launchStrong clinical alfapump profile demonstrated in North American POSEIDON studyAll approvals received to commence US...
June 26, 2023 12:00 ET | Source: Sequana Medical NV

Sequana Medical announces results of Special General Meeting of Shareholders

PRESS RELEASEREGULATED INFORMATION26 June 2023, 06:00 pm CEST Dr. Kenneth Macleod appointed as non-executive director Ghent, Belgium – 26 June 2023 – Sequana Medical NV (Euronext Brussels: SEQUA)...
June 21, 2023 01:00 ET | Source: Sequana Medical NV

Sequana Medical announces additional data on safety, quality of life and survival from North American pivotal alfapump® study (POSEIDON)

PRESS RELEASEREGULATED INFORMATION – INSIDE INFORMATION21 June 2023, 07:00 am CEST Data presented at EASL Congress 2023 alfapump was effective in the control of ascites, virtually eliminating...